Clinical Trial: Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System): Marker of Venous Thrombosis Risk in Systemic Lupus and Antiphospholipid Syndrom
Brief Summary:
The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event. This is a case-control study in a population with patients having systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APL).
Secondary purposes are:
- To determine the frequency of hypercoagulable phenotype in study population;
- To analyze the sensibility: consequences of variation of hypercoagulable phenotype threshold on the importance of risk;
- To identify (genetic and not) factors for hypercoagulable phenotype and their frequency in different groups.
Detailed Summary:
Sponsor: Central Hospital, Nancy, France
Current Primary Outcome:
- Thrombin potential measured with thrombinography [ Time Frame: baseline ]
- Measurement of IC50-APC (concentration of APC diminishing 50% thrombin potential at APC concentration = 0) [ Time Frame: baseline ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Central Hospital, Nancy, France
Dates:
Date Received: September 2, 2016
Date Started: September 2005
Date Completion:
Last Updated: September 8, 2016
Last Verified: September 2016
